Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...
Free to browse, no account needed Track IMCR with free AI briefings, catalyst countdowns, and dilution alerts.

IMCR · Immunocore Holdings plc

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$901.3M Cash on Hand
CF+ Cash Runway
Follow IMCR by email Get an email when IMCR reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about IMCR, unsubscribe in one click. Privacy

📣 What IMCR Says Is Next

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

📄 Latest SEC Filings in Plain English

Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.

🧪 Trial & FDA Catalysts

📊 Drug Pipeline

DrugIndicationMost advanced trialStatus
Tebentafusp (IMCgp100)
FDA approved Jan 2022 · Kimmtrak
Advanced Melanoma Phase 3 · NCT05549297 Recruiting
Brenetafusp Advanced Melanoma Phase 3 · NCT06112314 Recruiting
Investigators Choice Advanced Melanoma Phase 3 · NCT05549297 Recruiting
Monoclonal Antibody Cancer Phase 1/2 · NCT06840119 Recruiting
Kinase Inhibitor Cancer Phase 1/2 · NCT06840119 Recruiting
Anti-NY-ESO1/LAGE-1A TCR/scFv Anti-CD3 IMCnyeso Select Advanced Solid Tumors Phase 1/2 · NCT03515551 Terminated
IMC-R117C Cancer Phase 1/2 · NCT06840119 Recruiting
Anti-MAGE-A4 T-cell Receptor/Anti-CD3 scFv… Select Advanced Solid Tumors Phase 1/2 · NCT03973333 Withdrawn
Chemotherapy drug Cancer Phase 1/2 · NCT06840119 Recruiting
Angiogenesis Inhibitor Cancer Phase 1/2 · NCT06840119 Recruiting
IMC-P115C PRAME Positive Phase 1 · NCT07156136 Recruiting
IMC-I109V Single Ascending Dose Hepatitis B, Chronic Phase 1 · NCT05867056 Withdrawn
IMC-S118AI Type 1 Diabetes Phase 1 · NCT07493122 Not yet recruiting
IMC-I109V Multiple Ascending Doses Hepatitis B, Chronic Phase 1 · NCT05867056 Withdrawn
HBV HCC Module MAD Hepatitis B, Chronic Phase 1 · NCT05867056 Withdrawn

Also used in these trials (approved or third-party drugs, not IMCR's own candidates): Relatlimab, Nivolumab, Atezolizumab, Pembrolizumab, Ipilimumab, Dexamethasone, Dacarbazine.

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

💰 Cash Runway & Dilution Risk

IMCR holds $901.3M in cash and short-term investments (as of Sep 30, 2026) and its operations are currently cash-flow neutral or positive.

Dilution pressure: 0 · Low

Recent financing filings on SEC EDGAR:

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when IMCR files for a raise →

👥 Who Owns IMCR

Insiders 4.2% Other 5%+ holders 5.3% Institutions (173 holders) 90.5% Public and other holders 0%
HolderTypeShares% of sharesAs of
Wellington Management Group LLP Institution (13G, 5%+) 5,959,773 11.53% 2026-06-30
Point72 Asset Management, L.P. 5%+ holder (13G) 2,720,043 5.26% 2026-11-06
BAKER BROS. ADVISORS LP
Director · +39,123 options
Insider 2,144,060 4.15% 2025-03-17
Bahija Jallal
CHIEF EXECUTIVE OFFICER, Director · +889,463 options
Insider 12,343 0.02% 2026-02-17
David M Berman
HEAD OF R&D · +176,823 options
Insider 5,859 0.01% 2026-02-17
Leger Tina Amber St
CHIEF HR OFFICER · +29,569 options
Insider 1,119 0.00% 2026-02-17
John Goll
SVP, FINANCE & CAO · +43,465 options
Insider 653 0.00% 2026-02-17

Share count 51,681,376 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.

Get the full IMCR picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for IMCR and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z

This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.